EntreMed Inc. (ENMD)
-NasdaqCM 1.85 
0.02(1.07%) May 17, 3:52PM EDT
| Prev Close: | 1.87 |
|---|
| Open: | 1.86 |
|---|
| Bid: | 1.50 x 1000 |
|---|
| Ask: | 1.94 x 400 |
|---|
| 1y Target Est: | 1.00 |
|---|
| Beta: | 2.17 |
|---|
| Next Earnings Date: | 12-Aug-13 |
|---|
| Day's Range: | 1.80 - 1.91 |
|---|
| 52wk Range: | 1.23 - 3.73 |
|---|
| Volume: | 30,763 |
|---|
| Avg Vol (3m): | 79,176 |
|---|
| Market Cap: | 49.99M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.62 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- EntreMed Reports First Quarter 2013 Financial ResultsPR Newswire(Wed, May 15)
- ENTREMED INC Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Wed, May 15)
- Patent Issued In China For EntreMed's Lead Drug Candidate ENMD-2076PR Newswire(Mon, May 6)
- EntreMed announced issurance of U.S. patent for 2ME2theflyonthewall.com(Fri, May 3)
- Patent Issued In U.S. For EntreMed's 2ME2 In Rheumatoid DiseasesPR Newswire(Fri, May 3)
- ENTREMED INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsEDGAR Online(Tue, Apr 9)
- EntreMed Announces Changes to Board of Directors and CEO AppointmentPR Newswire(Fri, Apr 5)
- ENTREMED INC FinancialsEDGAR Online Financials(Tue, Mar 26)
- EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013PR Newswire(Thu, Mar 21)
- ENTREMED INC Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Thu, Mar 21)
- China Biotech In Review: WuXi PharmaTech Reports Another Year Of Steadily Increasing Growthat Seeking Alpha(Sun, Mar 10)
- ENTREMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Wed, Mar 6)
- Sabby Management reports 6.17% passive stake in EntreMedtheflyonthewall.com(Wed, Mar 6)
- The Daily Startup: Insiders Back Pathbrite for Multimedia E-Portfoliosat The Wall Street Journal(Mon, Mar 4)
- Burrill Securities Acts as Exclusive Placement Agent for EntreMed $10.7 Million Registered DirectMarketwired(Fri, Mar 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 75.50 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
EntreMed, Inc., a clinical-stage pharmaceutical company, engages in developing therapeutics to treat cancer and other diseases primarily in the United States and China.
View More